Literature DB >> 16918244

Inhibition of cellular respiration by doxorubicin.

Zhimin Tao1, Henry G Withers, Harvey S Penefsky, Jerry Goodisman, Abdul-Kader Souid.   

Abstract

Doxorubicin executes apoptosis, a process known to produce leakage of cytochrome c and opening of the mitochondrial permeability transition pores. To define the loss of mitochondrial function by apoptosis, we monitored cellular respiration during continuous exposure to doxorubicin. A phosphorescence analyzer capable of stable measurements over at least 5 h was used to measure [O(2)]. In solutions containing glucose and cells, [O(2)] declined linearly with time, showing that the kinetics of oxygen consumption was zero order. Complete inhibition of oxygen consumption by cyanide indicated that oxidations occurred in the respiratory chain. A decline in the rate of respiration was evident in Jurkat and HL-60 cells exposed to doxorubicin. The decline was abrupt, occurring after about 2 h of incubation. The inhibition was concentration-dependent and was completely blocked by the pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone. Respiration in resistant HL-60/MX2 cells, characterized by an altered topoisomerase II activity, was not inhibited by doxorubicin. A decline in cellular ATP was measured in Jurkat cells after 2-4 h of incubation with 20 microM doxorubicin, paralleling the decline in respiration rate. Thus, cells incubated with doxorubicin exhibit caspase-mediated inhibition of oxidative phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16918244     DOI: 10.1021/tx050315y

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  5 in total

1.  Kinetic studies on enzyme-catalyzed reactions: oxidation of glucose, decomposition of hydrogen peroxide and their combination.

Authors:  Zhimin Tao; Ryan A Raffel; Abdul-Kader Souid; Jerry Goodisman
Journal:  Biophys J       Date:  2009-04-08       Impact factor: 4.033

2.  Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2.

Authors:  Yuan Rong; Chun-Hui Yuan; Zhen Qu; Hu Zhou; Qing Guan; Na Yang; Xiao-Hua Leng; Lang Bu; Ke Wu; Fu-Bing Wang
Journal:  Sci Rep       Date:  2016-04-01       Impact factor: 4.379

3.  Proteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches.

Authors:  Ângela Fernandes; Maria M Azevedo; Olga Pereira; Belém Sampaio-Marques; Artur Paiva; Margarida Correia-Neves; Isabel Castro; Paula Ludovico
Journal:  Oncotarget       Date:  2015-10-13

4.  Antimicrobial Peptides as New Combination Agents in Cancer Therapeutics: A Promising Protocol against HT-29 Tumoral Spheroids.

Authors:  Mina Raileanu; Aurel Popescu; Mihaela Bacalum
Journal:  Int J Mol Sci       Date:  2020-09-22       Impact factor: 5.923

5.  p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors.

Authors:  Eduardo Cepeda Cañedo; Stephanie Totten; Ryuhjin Ahn; Paul Savage; Deanna MacNeil; Jesse Hudson; Chantal Autexier; Genevieve Deblois; Morag Park; Michael Witcher; Josie Ursini-Siegel
Journal:  JCI Insight       Date:  2021-02-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.